The risk of bone fractures in dementia patients receiving acetylcholinesterase inhibitors: a meta-analysis

Author:

Elhalag Rowan H.1,Chèbl Pensée1,Bayoumy Nervana M.2,Hassan Noheir Ashraf Ibrahem Fathy3,Hagar Hanan2,Abowafia Marwan1,Gaber Hamed1,Belal Mohamed Mohamed1,Shah Jaffer4,Motawea Karam R.1

Affiliation:

1. Faculty of Medicine, Alexandria University, Alexandria

2. University of Arkansas for Medical Sciences, Little Rock, Arkansas

3. Faculty of Medicine, Aswan University, Aswan, Egypt

4. Weill Cornell Medicine, New York, NY

Abstract

Aim: The authors aimed to conduct a meta-analysis to determine if acetylcholinesterase inhibitors may pose a direct threat, increasing the incidence of fractures in dementia patients. Methods: PubMed, Scopus, and Cochrane Library were searched. Inclusion criteria were any original studies that demonstrated the link between acetylcholinesterase inhibitors and the incidence of fracture in patients with dementia. RevMan(5.4) was used. Results: Seven observational studies were included. The total number of patients included in the acetylcholinesterase inhibitors group is 274 332 and 290 347 in the control group. The pooled analysis showed that the risk of bone fracture was not statistically different between dementia patients who received acetylcholinesterase inhibitors and those who did not receive them (odds ratio=1.44, CI 0.95, 2.19, P=0.09). Subgroup analysis showed no statistically significant difference between dementia patients who took acetylcholinesterase inhibitors, and those who didn’t take acetylcholinesterase inhibitors in those more than or equal to 80 years old and those less than 80 years old (P=0.44) and (P=0.34) respectively. However, our results showed a statistically significant association between dementia patients who received acetylcholinesterase inhibitors and decreased fracture risk in those receiving the treatment for more than or less than 2 years (risk ratio=0.48, CI= 0.45, 0.51, P<0.00001) and (risk ratio=0.84, CI 0.70, 0.99, P=0.04), respectively. Conclusion: Our study revealed no role for acetylcholinesterase inhibitors in increasing the risk of fracture compared with controls. Hence, based on our analysis, they might have a protective role against fracture when used for long periods considering their positive action on bone growth and development. Therefore, Acetylcholinesterase inhibitors could be considered a safe option for improving cognitive functions in elderly demented patients without carrying any additional risks.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference37 articles.

1. Cholinesterase inhibitors and beyond;Pepeu;Curr Alzheimer Res,2009

2. Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action;Poirier;Int J Clin Pract Suppl,2002

3. Selective loss of central cholinergic neurons in Alzheimer’s disease;Davies;Lancet,1976

4. Alzheimer’s disease and senile dementia: loss of neurons in the basal forebrain;Whitehouse;Science,1982

5. The neurochemistry of vascular dementia;Gottfries;Dement Geriatr Cogn Disord,1994

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3